U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H13BrN4S.ClH
Molecular Weight 373.699
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TROVIRDINE HYDROCHLORIDE

SMILES

Cl.BrC1=CC=C(NC(=S)NCCC2=CC=CC=N2)N=C1

InChI

InChIKey=IUQKLSJRANLIKE-UHFFFAOYSA-N
InChI=1S/C13H13BrN4S.ClH/c14-10-4-5-12(17-9-10)18-13(19)16-8-6-11-3-1-2-7-15-11;/h1-5,7,9H,6,8H2,(H2,16,17,18,19);1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C13H13BrN4S
Molecular Weight 337.238
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Trovirdine [LY 300046, LY 300082, PETT 1] is a NNRT inhibitor of HIV-1 RT, which progressed through Phase II trials for the treatment of HIV infection. Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM. Cell culture experiments demonstrated that LY300046 was a potent inhibitor of the replication of HIV-1 in human T-cell lines and human PBL, including spread of the virus from infected to uninfected T cells. It was potent against patient isolates as well as laboratory isolates of HIV-1 but was not active against HIV-2 or simian immunodeficiency virus.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Concentrations of LY300046 in the brain were similar to those in plasma at all of the time points examined, indicating that LY300046 readily crosses the blood-brain barrier in rats.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 7.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
2009-04
N2-benzyloxycarbonylguan-9-yl acetic acid derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors with decreased loss of potency against common drug-resistance mutations.
2007-10
Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
2006-07
Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
2005-06-02
PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide.
2004-12
Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.
2004-08-01
Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.
2004-05-15
Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
2003-02-27
Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase.
2002-12
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
2000-09-18
Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity.
2000-09
Novel thiourea compounds as dual-function microbicides.
2000-07
N-[2-(4-methylphenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1.
2000-03
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
1999-12-20
Prophylactic contraceptives for HIV/AIDS.
1999-12-03
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
1999-09-20
Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
1999-09
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
1999-06-07
Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity.
1999-06
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
1998-08-18
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
1998-06-16
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
1996-10-11
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
1995-12-08
Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.
1995-12
The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
1995-06
Patents

Patents

EP1466628A1
8
EP2912070A1
2

Sample Use Guides

In Vivo Use Guide
Rats were administered a single 20-mg/kg oral dose of Trovirdine [LY 300046].
Route of Administration: Oral
In Vitro Use Guide
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:48:46 GMT 2025
Edited
by admin
on Mon Mar 31 18:48:46 GMT 2025
Record UNII
70714531RJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TROVIRDINE HYDROCHLORIDE
Common Name English
LY-300046 HYDROCHLORIDE
Preferred Name English
TROVIRDINE HCL
Common Name English
THIOUREA, N-(5-BROMO-2-PYRIDINYL)-N'-(2-(2-PYRIDINYL)ETHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
5327620
Created by admin on Mon Mar 31 18:48:46 GMT 2025 , Edited by admin on Mon Mar 31 18:48:46 GMT 2025
PRIMARY
FDA UNII
70714531RJ
Created by admin on Mon Mar 31 18:48:46 GMT 2025 , Edited by admin on Mon Mar 31 18:48:46 GMT 2025
PRIMARY
CAS
148311-89-1
Created by admin on Mon Mar 31 18:48:46 GMT 2025 , Edited by admin on Mon Mar 31 18:48:46 GMT 2025
PRIMARY
Related Record Type Details
Structure of TROVIRDINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TROVIRDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966